None

For the Treatment of Asthma, Surveyed Physicians' Prescribing Practices of LABA/ICS Fixed-Dose Combinations (FDCs) Show that Competition is Tight Between GlaxoSmithKline's Seretide and AstraZeneca's Symbicort in Each EU5 Country

EU5 Payers Indicate that Emerging FDCs Will Likely Be Admitted for Reimbursement at the National Level But Warn that Reimbursement Price Will Depend on the Strength of Clinical Trial Data, Accordi...

GSK includes QR codes to aid compliance

GSK has added QR (quick response) codes to the packaging of its Seretide Accuhaler (salmeterol xinafoate/fluticasone propionate) device — indicated for both asthma and chronic obstructive pulmonary...

For the Treatment of Asthma, Surveyed Physicians’ Prescribing Practices of LABA/ICS Fixed-Dose Combinations (FDCs) Show that Competition is Tight Between GlaxoSmithKline’s Seretide and AstraZeneca’s Symbicort in Each EU5 Country

Decision Resources, one of the world’s leading research and advisory firms for pharmaceutical and healthcare issues, finds that, for the treatment of asthma, surveyed physicians...

The COPD Drug Market Will Become More Fractured as Several New Agents Reach the Market and Erode the Dominance of the Current Market Leaders

Decision Resources, one of the world’s leading research and advisory firms for pharmaceutical and healthcare issues, finds that the drug market for chronic obstructive pulmonary...

Interviewed EU5 Payers Stress that Demonstrating Superior Efficacy Over Leading Current Therapies in Head-to-Head Trials is Crucial for Favorable Reimbursement of LABA/LAMA Fixed-Dose Combinations

Decision Resources, one of the world’s leading research and advisory firms for pharmaceutical and healthcare issues, finds that interviewed payers in the EU5 (France, Germany, I...

For Chronic Obstructive Pulmonary Disease, Surveyed Pulmonologists Indicate That Improved Effect on Quality of Life is One of the Greatest Unmet Needs

BURLINGTON, Mass., May 20, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that surveyed U.S. and Europe...

Aquinox Pharmaceuticals Completes US $18 million Series C Financing

VANCOUVER, BRITISH COLUMBIA -- (Marketwired) -- 04/03/13 -- Aquinox Pharmaceuticals Inc., a private, venture-backed, pharmaceutical company developing novel and targeted small molecule therapeutics f...

Financings of the Fortnight Doesn't See Much To "Like"

 Without further ado, we bring you a few IPO notes from the Facebook Fiasco Fortnight. While most market watchers trained their eyes on Zuck, his biotech-veteran CFO, his bankers, and (eventually...

The 'stage-by-stage' deposition of drugs from commercial single-active and combination dry powder inhaler formulations.

Inhalation of salmeterol xinafoate (SX) and fluticasone propionate (FP) from a combination product is reported to produce superior clinical outcomes in comparison to the concurrent administration of '...

Comparison of heat-sensitive moxibustion versus fluticasone/salmeterol (seretide) combination in the treatment of chronic persistent asthma: design of a multicenter randomized controlled trial.

ABSTRACT: BACKGROUND: Asthma is a major health problem and has signicant mortality around the world. Although the symptoms can be controlled by drug treatment in most patients, effective low-risk, non...